139 related articles for article (PubMed ID: 31009566)
1. Functionally Versatile and Highly Stable Chelator for
Li L; Jaraquemada-Peláez MG; Kuo HT; Merkens H; Choudhary N; Gitschtaler K; Jermilova U; Colpo N; Uribe-Munoz C; Radchenko V; Schaffer P; Lin KS; Bénard F; Orvig C
Bioconjug Chem; 2019 May; 30(5):1539-1553. PubMed ID: 31009566
[TBL] [Abstract][Full Text] [Related]
2. Toward Bifunctional Chelators for Thallium-201 for Use in Nuclear Medicine.
Rigby A; Firth G; Rivas C; Pham T; Kim J; Phanopoulos A; Wharton L; Ingham A; Li L; Ma MT; Orvig C; Blower PJ; Terry SYA; Abbate V
Bioconjug Chem; 2022 Jul; 33(7):1422-1436. PubMed ID: 35801668
[TBL] [Abstract][Full Text] [Related]
3. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
[TBL] [Abstract][Full Text] [Related]
4. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
5. Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach.
Lahnif H; Grus T; Pektor S; Greifenstein L; Schreckenberger M; Rösch F
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770742
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
7. [
Li L; Jaraquemada-Peláez MG; Aluicio-Sarduy E; Wang X; Jiang D; Sakheie M; Kuo HT; Barnhart TE; Cai W; Radchenko V; Schaffer P; Lin KS; Engle JW; Bénard F; Orvig C
Inorg Chem; 2020 Feb; 59(3):1985-1995. PubMed ID: 31976659
[No Abstract] [Full Text] [Related]
8. H(2)azapa: a versatile acyclic multifunctional chelator for (67)Ga, (64)Cu, (111)In, and (177)Lu.
Bailey GA; Price EW; Zeglis BM; Ferreira CL; Boros E; Lacasse MJ; Patrick BO; Lewis JS; Adam MJ; Orvig C
Inorg Chem; 2012 Nov; 51(22):12575-89. PubMed ID: 23106422
[TBL] [Abstract][Full Text] [Related]
9. H(4)octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy.
Price EW; Zeglis BM; Cawthray JF; Ramogida CF; Ramos N; Lewis JS; Adam MJ; Orvig C
J Am Chem Soc; 2013 Aug; 135(34):12707-21. PubMed ID: 23901833
[TBL] [Abstract][Full Text] [Related]
10. Enhancing Treatment Efficacy of
Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
12. Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile.
Deberle LM; Tschan VJ; Borgna F; Sozzi-Guo F; Bernhardt P; Schibli R; Müller C
Molecules; 2020 May; 25(11):. PubMed ID: 32486054
[TBL] [Abstract][Full Text] [Related]
13. What a difference a carbon makes: H₄octapa vs H₄C3octapa, ligands for In-111 and Lu-177 radiochemistry.
Price EW; Zeglis BM; Cawthray JF; Lewis JS; Adam MJ; Orvig C
Inorg Chem; 2014 Oct; 53(19):10412-31. PubMed ID: 25192223
[TBL] [Abstract][Full Text] [Related]
14. Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.
Kratochwil C; Afshar-Oromieh A; Kopka K; Haberkorn U; Giesel FL
Semin Nucl Med; 2016 Sep; 46(5):405-18. PubMed ID: 27553466
[TBL] [Abstract][Full Text] [Related]
15. Toward
Lepage ML; Kuo HT; Roxin Á; Huh S; Zhang Z; Kandasamy R; Merkens H; Kumlin JO; Limoges A; Zeisler SK; Lin KS; Bénard F; Perrin DM
Chembiochem; 2020 Apr; 21(7):943-947. PubMed ID: 31621172
[TBL] [Abstract][Full Text] [Related]
16.
Sinnes JP; Bauder-Wüst U; Schäfer M; Moon ES; Kopka K; Rösch F
EJNMMI Radiopharm Chem; 2020 Nov; 5(1):28. PubMed ID: 33242189
[TBL] [Abstract][Full Text] [Related]
17. A systematic study on the utility of CHX-A''-DTPA-NCS and NOTA-NCS as bifunctional chelators for
Pandey U; Gamre N; Lohar SP; Dash A
Appl Radiat Isot; 2017 Sep; 127():1-6. PubMed ID: 28478331
[TBL] [Abstract][Full Text] [Related]
18. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
[TBL] [Abstract][Full Text] [Related]
19. p-NO
Spreckelmeyer S; Ramogida CF; Rousseau J; Arane K; Bratanovic I; Colpo N; Jermilova U; Dias GM; Dude I; Jaraquemada-Peláez MG; Bénard F; Schaffer P; Orvig C
Bioconjug Chem; 2017 Aug; 28(8):2145-2159. PubMed ID: 28683198
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo evaluation of the bifunctional chelator NODIA-Me in combination with a prostate-specific membrane antigen targeting vector.
Läppchen T; Kiefer Y; Holland JP; Bartholomä MD
Nucl Med Biol; 2018 May; 60():45-54. PubMed ID: 29571066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
